Abstract-The lipid products derived from the cyclooxygenase pathway can have diverse and often contrasting effects on vascular cell function. Cyclopentenone prostaglandins (cyPGs), such as 15-deoxy-⌬ 12,14 -prostaglandin-J 2 (15d-PGJ 2 ), a peroxisome proliferator-activated receptor-␥ (PPAR␥) agonist, have been reported to cause endothelial cell apoptosis, yet in other cell types, cyPGs induce cytoprotective mediators, such as heat shock proteins, heme oxygenase-1, and glutathione (GSH). Herein, we show in human endothelial cells that low micromolar concentrations of 15d-PGJ 2 enhance GSH-dependent cytoprotection through the upregulation of glutamate-cysteine ligase, the rate-limiting enzyme of GSH synthesis, as well as GSH reductase. The effect of 15d-PGJ 2 on GSH synthesis is attributable to the cyPG structure but is independent of PPAR, inasmuch as the other cyPGs, but not PPAR␥ or PPAR␣ agonists, are able to increase GSH. The increase in cellular GSH is accompanied by abrogation of the proapoptotic effects of 4-hydroxynonenal, a product of lipid peroxidation present in atherosclerotic lesions. However, higher concentrations of 15d-PGJ 2 (10 mol/L) cause endothelial cell apoptosis, which is further enhanced by depletion of cellular GSH by buthionine sulfoximine. We propose that the GSH-dependent cytoprotective pathways induced by 15d-PGJ 2 contribute to its antiatherogenic effects and that these pathways are distinct from those leading to apoptosis. Key Words: cyclopentenone prostaglandins Ⅲ glutathione Ⅲ glutamate-cysteine ligase Ⅲ endothelium Ⅲ apoptosis P rostaglandins of the J series (PGJs) are cyclopentenones synthesized from arachidonic acid via enzymatic conversion by cyclooxygenase and prostaglandin D 2 (PGD 2 ) synthase, followed by nonenzymatic dehydration of PGD 2 to PGJ 2 , ⌬ 12 -PGJ 2 , and 15-deoxy-⌬ 12,14 -PGJ 2 (15d-PGJ 2 ). 1 These compounds have generated considerable interest in vascular biology after the discovery of their ability to activate one of the ligand-activated nuclear receptors, peroxisome proliferator-activated receptor-␥ (PPAR␥). 2 Through a mechanism in which 15d-PGJ 2 acts as a PPAR␥ agonist, it has been shown to inhibit production of proinflammatory cytokines in monocytes and the binding of these cells to the endothelium. 3,4 However, cyclopentenone prostaglandins (cyPGs) have also PPAR-independent anti-inflammatory effects, including inhibition of nuclear factor-B activation by inhibiting IB kinase. 5,6 This is important in atherogenesis, because some of the early events in lesion formation, such as monocyte recruitment and adherence, are mediated by nuclear factor-B-dependent upregulation of monocyte chemoattractant protein-1, as well as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. 7 Moreover, cyPGs induce cytoprotective mediators, such as heat shock proteins, heme oxygenase-1, and glutathione (GSH), further strengthening the notion that cyPGs are potentially antiatherogenic. 8 -10 However, cyPGs have also been shown to be cytostatic or cytoto...